Introduction
============

Spinal cord injury (SCI) is a severe condition of the central nervous system, which represents a severe health problem that is associated with life-long disabilities and high mortality ([@b1-mmr-17-01-0771]--[@b3-mmr-17-01-0771]). The WHO reported in November 2013 that worldwide, 250,000--500,000 people annually suffer a spinal cord injury ([@b4-mmr-17-01-0771]). It is well known that in addition to white matter axon damage, oligodendrocyte cell death ([@b5-mmr-17-01-0771]) and demyelination in spared axons ([@b6-mmr-17-01-0771]--[@b9-mmr-17-01-0771]) may lead to the initial deficits associated with human SCC and impair functional recovery, which represents a challenge for the effective treatment of SCI. Oligodendrocytes are cells that produce the myelin sheath, which have been observed to die hours to weeks after SCI, near and distant to the epicenter, leading to demyelination ([@b10-mmr-17-01-0771]--[@b16-mmr-17-01-0771]). Therefore, therapeutic measures are required to reduce oligodendrocyte death and/or to enhance remyelination. Replacing lost oligodendrocytes, preventing the progression of demyelination or promoting remyelination is critical for functional recovery following SCC. In previous years, the advancement of cell therapy for SCI has been encouraging ([@b17-mmr-17-01-0771],[@b18-mmr-17-01-0771]). Cell transplantation has been reported to promote neuroprotection by releasing trophic factors, providing a growth-promoting matrix for regeneration of axons or replacing lost cells ([@b19-mmr-17-01-0771]). However, mature oligodendrocytes are unable to remyelinate naked axons in SCI, and also inhibit axonal regeneration by releasing myelin-associated inhibitors, including Nogo, myelin-associated glycoprotein and oligodendrocyte myelin glycoprotein ([@b20-mmr-17-01-0771],[@b21-mmr-17-01-0771]). Therefore, to the best of our knowledge, no studies regarding the treatment of SCI with oligodendrocyte transplantation have been conducted. However, with the progress made regarding neural development, more studies have reported the possibility of using oligodendrocyte precursor cell (OPC) transplantation for the treatment of demyelinating diseases, including SCC ([@b22-mmr-17-01-0771],[@b23-mmr-17-01-0771]). Therefore, OPC transplantation may be considered a potential therapy for the treatment of SCI ([@b24-mmr-17-01-0771]).

It has been reported that human embryonic stem cell (hESC)-derived OPC transplantation may attenuate lesion pathogenesis and improve recovery of forelimb function in rats with cervical SCC ([@b25-mmr-17-01-0771]). In addition, hESC-derived OPC transplantation into SCI sites in adult rats resulted in remyelination and functional repair ([@b22-mmr-17-01-0771]). Combined treatment with OPC grafts expressing ciliary neurotrophic factor (CNTF) can also enhance remyelination and facilitate functional recovery following SCC ([@b26-mmr-17-01-0771]). However, the molecular mechanism underlying the effects of OPC transplantation on SCI treatment, particularly regarding microRNA (miRNA) expression, is not fully understood.

miRNAs are \~23 nucleotide long endogenous ribonucleic acid molecules that specifically pair with the 3′ untranslated region of target mRNAs post-transcription, in order to direct mRNA degradation and suppress protein translation ([@b27-mmr-17-01-0771]--[@b29-mmr-17-01-0771]). Accumulating evidence has indicated that miRNAs serve crucial roles in various human diseases, including cancer, metabolic diseases, cardiovascular diseases, viral infections and contusive neurological injuries ([@b30-mmr-17-01-0771],[@b31-mmr-17-01-0771]). miRNAs are also involved in numerous cellular processes, including development, proliferation and differentiation ([@b28-mmr-17-01-0771],[@b32-mmr-17-01-0771]). Furthermore, numerous miRNAs have been detected in the mammalian central nervous system, including the brain and spinal cord, where they have key roles in neurodevelopment and are likely to be important mediators of plasticity ([@b33-mmr-17-01-0771]--[@b36-mmr-17-01-0771]). In addition, altered miRNA expression has been revealed in the spinal cord following SCC through microarray analysis ([@b37-mmr-17-01-0771],[@b38-mmr-17-01-0771]). However, whether miRNAs are involved in the regulatory effects of OPC transplantation on the spinal cord of rats with SCC remains unclear.

In the present study, following OPC transplantation into the spinal cord of rats with SCC, the Basso, Beattie and Bresnahan (BBB) score and pain value were determined, in order to assess functional recovery of rats. Subsequently, a miRNA assay was performed to detect the differentially expressed miRNAs in the spinal cord of rats with SCC and OPC transplantation compared with in rats with SCC and medium transplantation. Furthermore, quantitative polymerase chain reaction (qPCR) was used to verify the significantly altered miRNA expression. These results may identify the regulatory effects of miRNA in rats with SCC following OPC transplantation, which may provide a novel potential molecular target for the clinical treatment of SCI in the future.

Materials and methods
=====================

### Induced pluripotent stem cell (iPSC) preparation

The present study was approved by the ethics committee of Kunming Medical University (Kunming, China; KMMU2015013). Two pregnant mice were purchased from the Experimental Animal Center of Kunming Medical University. Mice were housed in cages at 22±2°C with 55±5% humidity under a 12-h light/dark cycle with free access to food and water. The skin of green fluorescent protein (GFP)-transgenic fetuses, obtained from 13.5-day-pregnant mice, was cut into small pieces and the skin samples were digested using 0.25% trypsin. Subsequently, cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at 37°C with 5% CO~2~. On the same day, fetal skin cells were co-transfected with 100 µl Moloney-based retroviral vectors (provided by Su Liu, Johns Hopkins University, Baltimore, MD, USA) that expressed octamer-binding transcription factor 3/4 (Oct3/4), sex determining region Y box-2 Sox2), c-Myc and Kruppel-like factor 4 (Klf4) (Oct3/4: Sox2: c-Myc: Klf4=1:1:1:1) which were transfected into PlatE clles using FuGENE 6 transfection reagent (Roche Diagnostics, Basel, Switzerland), twice within 2 days. On day 5 post-transfection, the transfected cells (1×10^5^) were inoculated into mouse embryonic fibroblasts (MEFs; MTI-GlobalStem, Gaithersburg, MD, USA) that were pre-processed with 10 µg/ml mitomycin (cat. no. 01035, BBI Solutions, Cardiff, UK) for 1 day. Subsequently, the medium was replaced with embryonic stem cell growth medium (Invitrogen; Thermo Fisher Scientific, Inc.) every day. On day 16, iPSC clones were picked, digested using trypsin and inoculated into radiated MEFs that served as a feeder layer to obtain amplification.

### iPSC differentiation

The iPSCs were cultured as aforementioned. iPSCs were separated by 0.25% trypsin every 4 days until passage 3 and were incubated with collagenase IV (1% in DMEM/F12; Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C for 15 min in order to separate them from MEFs. After 4 days, iPSCs cultured in stem cell differentiation medium became embryonic bodies. Subsequently, the embryonic bodies were incubated with tretinoin (all-trans-retinoic acid, 500 nM; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and purmorphamin (1 µm; Calbiochem; EMD Millipore, Billerica, MA, USA) for 4 days at 37°C. The stem cell differentiation medium consisted of 50% DMEM/F12 (Gibco; Thermo Fisher Scientific, Inc.), 50% Neurobasal medium (Gibco; Thermo Fisher Scientific, Inc.), 1% N2 (Gibco; Thermo Fisher Scientific, Inc.), 1% B27 (Gibco; Thermo Fisher Scientific, Inc.), 10% serum fluid replacement, 0.1 mM mercaptoethanol (Sigma-Aldrich; Merck KGaA), 2 mM Glutamax (Gibco; Thermo Fisher Scientific, Inc.) and 2 µg/ml heparin (Sigma-Aldrich; Merck KGaA). A total of 24 days were required for iPSC preparation and differentiation.

### Culture of iPSC-induced OPCs

At the 8th day of differentiation stage, the medium was replaced with OPC^+^ medium supplemented with platelet-derived growth factor (PDGF) and the cells were continually cultured for 8--10 days. Subsequently, cells were inoculated into plates that were coated with poly-D-lysine/laminin (BioCoat; BD Biosciences, Franklin Lakes, NJ, USA) at 37°C to proliferate for 2--3 days. The OPC^+^ medium contained 48% neurobasal medium (Gibco; Thermo Fisher Scientific, Inc.), 48% ml DMEM/F12 (Gibco; Thermo Fisher Scientific, Inc.), 50X OPC medium (Johns Hopkins University, Baltimore, MD, USA) 1/50 ml, 1% penicillin-streptomycin (Gibco; Thermo Fisher Scientific, Inc.), 0.5% Glutamax (Invitrogen; Thermo Fisher Scientific, Inc.), 1% non-essential amino acids and 0.02% fibroblast growth factor.

### Animal care and grouping

A total of 32 male Sprague-Dawley rats (7 weeks-old, weight, 200--250 g) were purchased from the Experimental Animal Center of Kunming Medical University and were randomly divided into four groups: Sham, SCC, SCC + medium (Medium) and SCC + OPC transplantation (OPC) groups ([Table I](#tI-mmr-17-01-0771){ref-type="table"}). All animal care, breeding and testing procedures conformed to the principles of guidance suggested in the National Institutes of Health Guide for the Care and Use of Laboratory Animals and supported by the Use Committee of Kunming Medical University. Rats were housed in cages at 22±2°C with 55±5% humidity under a 12-h light/dark cycle with free access to food and water.

### Animal model

SCC was performed to induce SCI in the present study. The rats were anesthetized by intraperitoneal injection with 3.6% chloral hydrate (380 mg/kg) and were placed in the prone position. A surgical incision was made in the thoracic region (T9-T11), and the paravertebral muscles and supraspinal ligaments were separated. Subsequently, the rats underwent a T9-T11 laminectomy, and were subjected to SCC at T10 level using a 10 g weight that was dropped from a 30 mm height. In addition, rats in the Sham group underwent the laminectomy only. Finally, the surgical wounds were sutured with a 3--0 silk suture. The rats were then injected with 5 ml saline, and received 0.5 ml cefotaxime sodium for 7 days and 0.05 ml Ciclosporin A injection (Novartis International AG, Basel, Switzerland) for 28 days. Their bladders were manually compressed three times a day until recovery of the micturition reflex.

### Immunofluorescence staining

Immunofluorescence staining of the differentiated cells was performed as follows. Briefly, after OPCs were fixed with 4% paraformaldehyde for 10 min, they were washed three times (5 min each) with PBS (0.01 mol/l). OPCs were subsequently incubated with 0.3% Triton X-100 for 30 min at 37°C and 5% goat serum for 30 min at 37°C, respectively, and incubated with the primary antibody against PDGF (1:100; Neomarkers, Inc., Fremont, CA) to identify OPCs ([@b39-mmr-17-01-0771]), at 4°C for 24 h. Finally, OPCs were washed using 0.01 mol/l PBS three times and incubated with Cy3 (1:100; Abcam, Cambridge, UK) for 60 min at 37°C. The nuclei were stained using DAPI and images were captured under a Leica DMI6000B (LAS AF system; Leica Microsystems, Inc., Buffalo Grove, IL, USA).

### OPC transplantation

Rats in each group were placed in the prone position and their vertebral laminae were reopened 7 days after SCC surgery. Subsequently, 5 µl cell suspensions (2×10^5^ cells/µl) were transplanted into each rat at two different sites at the rostral and tail end of the injury with a constant speed of 2.5 µl/min using a micropipette. The microinjector was maintained in the injection site for 5 min prior to removal. The Medium group was treated with OPC^+^ culture medium using the same procedure, while the vertebral laminae of rats in the sham and SCC control groups were re-opened without transplanting OPC or OPC^+^ culture medium.

### Assessment of locomotion recovery

Locomotion recovery of rats was evaluated using the BBB Locomotion Rating Scale ([@b40-mmr-17-01-0771]). The BBB scores range between 0 and 21. Score 0 indicates flaccid paralysis, whereas score 21 indicates normal gait. Three investigators, blinded to the experimental groups, performed behavioral experiments for rats in the Sham, SCC, Medium and OPC groups, in order to reduce the error of subjectivity. The assessments were performed on days 1, 3, 7, 14, 21 and 28 days following the transplantation operation in an open field ([@b41-mmr-17-01-0771]). The average score from the three investigators was considered the final score.

### Detection of mechanical pain threshold

Mechanical pain threshold assessments were performed on days 1, 3, 7, 14, 21 and 28 following the operation. Briefly, prior to the paw withdrawal threshold test, the value of the instrument was adjusted to zero. As the weight increased, the pressure that the rat felt was gradually increased. When the maximum pressure was reached it was recorded. This test was repeated three times and interval time was maintained at ≥10 min.

### Tissues collection

After the rats were anesthetized by intraperitoneal injection with 3.6% chloral hydrate (380 mg/kg), spinal cord tissues were harvested from Medium and OPC group rats 7 days following the OPC/medium transplantation operation. The samples were stored at −80°C for miRNA microarray analysis and qPCR.

### miRNA microarray analysis

Samples were transported to Genminix Informatics Co., Ltd. (Shanghai, China) for miRNA microarray analysis. Briefly, total RNA was extracted from the spinal cord samples using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), quantified and assessed for quality using a Nanodrop ND-1000 (Thermo Fisher Scientific, Inc., Wilmington, DE, USA), and reverse transcribed into cDNA using SuperScript II Reverse Transcriptase (cat. no. 18064014, Invitrogen; Thermo Fisher Scientific, Inc.). Subsequently, the cDNA samples were hybridized to the Affymetrix Gene 2.0 Array (Affymetrix; Thermo Fisher Scientific, Inc.) to detect differentially expressed miRNAs. Subsequently, the positive signal was recorded using an Axon GenePix 4000B scanner (Molecular Devices, LLC, Sunnyvale, CA, UAS). The scanned images were imported into GenePix Pro 6.0 software (Axon Instruments; Molecular Devices, LLC) for grid alignment and data extraction. All microarray signals were analyzed by subtracting the background and were normalized using median normalization. Following normalization, differentially expressed miRNAs were identified according to fold change. In all samples, only miRNAs with a fold change \>2 and P\<0.05 were defined as significant.

### Bioinformatics analysis of differentially expressed miRNAs

Initially, the target genes of the miRNAs were identified using the following prediction databases: miRecords ([c1.accurascience.com/miRecords/](c1.accurascience.com/miRecords/)), TargetScan ([www.targetscan.org/vert_71/](www.targetscan.org/vert_71/)), MicroCosm ([www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/](www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/)), miRanda ([www.microrna.org/microrna/home.do](www.microrna.org/microrna/home.do)) and PicTar ([pictar.mdc-berlin.de/](pictar.mdc-berlin.de/)), and genes that were identified across two or more databases were selected for further analysis. Subsequently, a Gene Ontology (GO; [www.geneontology.org/](www.geneontology.org/)) enrichment analysis was conducted to determine the significantly enriched biological processes associated with the target genes of the differentially expressed miRNAs. Furthermore, predicted target genes of the differentially expressed miRNAs were analyzed using a functional method mapping genes to Kyoto Encyclopedia of Genes and Genomes (KEGG; [www.genome.jp/kegg/](www.genome.jp/kegg/)) pathways.

### qPCR

Total RNA was extracted from the spinal cord samples of rats in the Medium and SCC groups using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), after which RNA was reverse transcribed to produce cDNA using an reverse transcribed reagent kit (Takara Bio, Inc.). Subsequently, the expression levels of miR-375-3p, miR-1-3p, miR-363-3p, miR-449a-5p and miR-3074 were analyzed using an SYBR Green RT-PCR Master Mix Kit (Takara Bio, Inc.). The primers were provided by Guangzhou RiboBio Co., Ltd. (Guangzhou, China) and the catalogue numbers are provided in [Table II](#tII-mmr-17-01-0771){ref-type="table"}. β-actin was used as an internal control; the primer sequences and annealing temperature for β-actin were as follows: Forward 5′-GCCAACACAGTGCTGTCT-3′ and reverse 5′-GGAGCAATGATCTTGATCTT-3′; annealing temperature, 53°C. The reaction was performed at 95°C for 2 min and 40 cycles of 95°C for 20 sec, 53°C for 30 sec and 60°C for 40 sec. Data were analyzed using the quantification cycle (Cq) method ([@b42-mmr-17-01-0771]), and target gene expression was normalized to internal control expression.

### Statistical analysis

All data are presented as the mean ± standard deviation. SPSS 17.0 (SPSS, Inc., Chicago, IL, USA) was used to analyze the data. Differences between two groups were assessed using a t-test and among multiple groups using one-way analysis of variance followed by least significant difference. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identification of GFP-OPCs induced from iPSCs derived from MEFs

To identify the characteristics of GFP-OPCs induced from iPSCs derived from MEFs, they were cultured for 24 days in differentiation medium ([Fig. 1](#f1-mmr-17-01-0771){ref-type="fig"}). When GFP-OPCs were cultured in basal-OPC-medium supplemented with PDGF, almost all of the cells displayed the typical morphology of OPCs ([Fig. 1C](#f1-mmr-17-01-0771){ref-type="fig"}), and \>90% of cells expressed PDGF ([Fig. 1A and D](#f1-mmr-17-01-0771){ref-type="fig"}).

### Transplantation of OPCs promotes motor and sensory recovery of rats subjected to SCC

To investigate the effects of OPC transplantation on the motor and sensory function of rats subjected to SCC, BBB and paw withdrawal threshold analyses were conducted on rats from the Sham, SCC, Medium and OPC groups. As presented in [Fig. 2A](#f2-mmr-17-01-0771){ref-type="fig"}, with the exception of day 1 and 3, post-transplantation, the BBB score demonstrated that rats in the OPC group exhibited significant motor improvement compared with those in the Medium group. Results of the paw withdrawal threshold analysis indicated that OPCs attenuated SCC-induced mechanical allodynia. Days 1 and 3 post-transplantation, there were no significant differences between the average paw withdrawal threshold for rats in the Medium and OPC groups. However, 7, 14, 21 and 28 days following the transplantation, the OPC group exhibited a marked attenuation of mechanical allodynia (i.e. an increase in paw-withdrawal threshold) compared with in the Medium group ([Fig. 2B](#f2-mmr-17-01-0771){ref-type="fig"}).

### miRNA expression profile in the spinal cord of rats in the OPC group compared with the Medium group

A miRNA assay was conducted on spinal cords obtained from rats in the OPC and Medium groups. The results indicated that there were 45 differentially expressed miRNAs (40 upregulated and 5 downregulated) in the spinal cord of rats from the OPC group compared with in the Medium group, according to the following criteria: Fold change \>2 and P\<0.05 ([Table III](#tIII-mmr-17-01-0771){ref-type="table"}). The top 10 upregulated miRNAs were rno-miR-1-3p, rno-miR-496-3p, rno-miR-758-3p, rno-miR-206-3p, rno-miR-375-3p, rno-miR-133a-3p, rno-miR-379-3p, rno-miR-335, rno-miR-133b-3p and rno-miR-21-3p, the 5 downregulated miRNAs were rno-miR-92a-1-5p, rno-miR-449a-5p, rno-miR-363-3p, rno-miR-449c-3p and rno-miR-3074 ([Fig. 3A](#f3-mmr-17-01-0771){ref-type="fig"}). A heat map of the miRNAs is presented in [Fig. 3B](#f3-mmr-17-01-0771){ref-type="fig"}.

### GO analysis of the target genes of altered miRNAs

It has previously been reported that miRNAs regulate gene expression by controlling protein translation or destabilizing mRNA transcripts ([@b29-mmr-17-01-0771],[@b43-mmr-17-01-0771]). Therefore, using prediction databases (miRecords, TargetScan, MicroCosm, Miranda and Pictar), the target genes of all of the altered miRNAs were screened. Subsequently, the main functional categories associated with the target genes were identified by GO analysis. The results identified 578 significantly enriched GO terms by analyzing the target genes of the 40 upregulated miRNAs (P\<0.05); the top 10 GO terms are presented in [Fig. 4A](#f4-mmr-17-01-0771){ref-type="fig"}. In addition, 185 significantly enriched GO terms were identified by analyzing the target genes of the 5 downregulated miRNAs (P\<0.05); the top 10 GO terms are shown in [Fig. 4B](#f4-mmr-17-01-0771){ref-type="fig"}.

### KEGG pathways associated with the target genes of altered miRNAs

A KEGG pathway analysis was performed for the target genes of all of the differentially expressed miRNAs. The results identified 107 associated pathways by analyzing the target genes of the 40 upregulated miRNAs (P\<0.05); the top 10 pathways are presented in [Fig. 5A](#f5-mmr-17-01-0771){ref-type="fig"}. In addition, 14 associated pathways were identified by analyzing the target genes of the 5 downregulated miRNAs (P\<0.05); the top 10 pathways are presented in [Fig. 5B](#f5-mmr-17-01-0771){ref-type="fig"}.

### qPCR verification of OPC transplantation-responsive spinal cord miRNAs from rats subjected to SCC

In order to validate the expression profiles generated from the miRNA assay, a qPCR analysis was performed to identify the association between the two datasets. As presented in [Fig. 6](#f6-mmr-17-01-0771){ref-type="fig"}, the most highly upregulated (miR-375-3p and miR-1-3p) and downregulated (miR-363-3p, miR-449a-5p and miR-3074) spinal cord miRNAs identified in the miRNA assay were further verified, and showed consistent alterations, in a qPCR analysis.

### Bioinformatics analysis of the important and verified miRNAs

The results of the qPCR analysis demonstrated that miR-375 and miR-1 were upregulated in the OPC group compared with in the Medium group, and a bioinformatics analysis indicated that they targeted similar types of genes; therefore, miR-375 and miR-1 were grouped together for functional analysis. The results suggested that miR-375 and miR-1 may act primarily to inhibit cell proliferation and apoptosis through the regulation of transcription and translation. Furthermore, due to their association within the same annotation cluster (such as cell proliferation), it is possible that the primary method by which these two miRNAs regulate cell proliferation is via the inhibition of GO terms, including the mitogen-activated protein kinases signaling pathway ([Table IV](#tIV-mmr-17-01-0771){ref-type="table"}). miR-363, miR-449a and miR-3074 were downregulated in the OPC group compared with in the Medium group, as confirmed by qPCR, and a bioinformatics analysis demonstrated that they targeted similar types of genes; therefore, miR-363, miR-449a and miR-3074 were grouped together for functional analysis. The results indicated that miR-363, miR-449a and miR-3074 may primarily inhibit cell proliferation and neuronal differentiation through the regulation of transcription ([Table IV](#tIV-mmr-17-01-0771){ref-type="table"}).

Discussion
==========

Human SCC can cause severe and long-term disability ([@b3-mmr-17-01-0771]). At present, there is no effective clinical treatment for functional recovery following SCI. However, it has been reported that OPC transplantation may have potential for the treatment of SCI ([@b44-mmr-17-01-0771],[@b45-mmr-17-01-0771]), and abnormal miRNA expression may contribute to the pathogenesis of SCI ([@b37-mmr-17-01-0771]). However, to the best of our knowledge, there are no reports regarding the expression of miRNAs in the spinal cord of rats following SCC and OPC transplantation. The present study aimed to investigate the effects of OPC transplantation on rats with SCC; initially, BBB score and paw withdrawal threshold were tested following OPC transplantation into the spinal cord of rats with SCC. Subsequently, in order to detect the differentially expressed miRNAs in the spinal cord of rats in the OPC group compared with in the Medium group, a miRNA assay was conducted. Finally, qPCR was performed to verify the significantly altered miRNAs.

Firstly, following identification of OPCs, the cells were transplanted into rats that were subjected to SCC for 7 days. The BBB score demonstrated that OPC transplantation was able to improve the motor recovery of rats with SCC. A previous study demonstrated that OPC transplantation improved forelimb motor function following cervical SCI ([@b25-mmr-17-01-0771]). In addition, animals that were subjected to SCC and hESC-derived OPCs transplantation at 7 days performed significantly better on the BBB locomotor test compared with those transplanted with human fibroblasts or DMEM ([@b22-mmr-17-01-0771]). Furthermore, CNTF-OPC-grafted animals exhibited significantly increased BBB locomotor scores compared with those receiving DMEM, enhanced green fluorescent protein (EGFP)-fibroblasts or CNTF-fibroblasts at 3--7 weeks following injury; the BBB scores of the EGFP-OPC-grafted animals were also significantly higher than the other three groups at 5--7 weeks following injury ([@b26-mmr-17-01-0771]). In the present study, paw withdrawal testing indicated that OPC transplantation may relieve SCC-induced mechanical allodynia. It has previously been reported that transplanted hESC-derived OPCs promoted repair of the sensory pathways of rats with SCC ([@b46-mmr-17-01-0771]). The results of the present study were concordant with those of the previous aforementioned studies.

The results of a miRNA assay detected 40 upregulated miRNAs and 5 downregulated miRNAs in the spinal cord of rats from the OPC group compared with in the Medium group, according to the following criteria: Fold change \>2 and P\<0.05. Bioinformatics analysis indicated that positive regulation of transcription from RNA polymerase II promoter was the most significantly enriched GO term, and metabolic pathways was the most significantly enriched KEGG pathway, according to the number of target genes of differentially expressed miRNAs enriched in them. A previous study detected 97 differentially expressed miRNAs in the adult rat spinal cord following traumatic SCI through miRNA analysis, and the potential targets for these SCI-altered miRNAs included genes associated with inflammation, oxidation and apoptosis, which are known to serve important roles in the pathogenesis of SCI ([@b37-mmr-17-01-0771]). Furthermore, microarray comparisons of the injury sites of spinal cords from contused and sham rats, harvested 4 and 14 days following SCC, demonstrated that 32 miRNAs, including miR-124, miR-129, and miR-1, were significantly downregulated. In addition, a bioinformatics analysis of validated miRNA-targeted genes indicated that miRNA dysregulation may explain the apoptotic susceptibility and aberrant cell cycle associated with a loss of neuronal identity, which underlies the pathogenesis of secondary SCC ([@b38-mmr-17-01-0771]). Furthermore, microarray data has previously revealed that the induction of a specific miRNA expression pattern following moderate SCC is characterized by a marked increase in the number of downregulated miRNAs, particularly at 7 days after injury, and a bioinformatics analysis indicated that alterations in miRNA expression may affect key processes in SCI physiopathology, including inflammation and apoptosis ([@b31-mmr-17-01-0771]). To the best of our knowledge, the present study is the first to report that dysregulated miRNA expression is present in the spinal cord of SCC rats transplanted with OPCs compared with in SCC rats treated with medium.

The present study also demonstrated that the most highly upregulated (miR-375-3p and miR-1-3p) and downregulated (miR-363-3p, miR-449a-5p and miR-3074) spinal cord miRNAs identified in the miRNA assay were consistently altered in a qPCR analysis. Furthermore, functional analysis demonstrated that miR-375 and miR-1 may primarily act to inhibit cell proliferation and apoptosis through the regulation of transcription and translation, whereas miR-363, miR-449a and miR-3074 may primarily act to inhibit cell proliferation and neuronal differentiation through the regulation of transcription. A previous study demonstrated that overexpression of miR-375 significantly inhibited gastric cancer cell proliferation by targeting Janus kinase 2 *in vitro* and *in vivo* ([@b47-mmr-17-01-0771]). In addition, by regulating the expression of B-cell lymphoma (Bcl)-2, Bcl-2-associated X protein and miR-375 *in vitro* and *in vivo*, formononetin was able to induce apoptosis of U2OS human osteosarcoma cells ([@b48-mmr-17-01-0771]). miR-375 could also affect the proliferation and apoptosis of human papilloma virus 16-positive human cervical cancer cells by targeting insulin-like growth factor 1 receptor ([@b49-mmr-17-01-0771]). In addition, it has been reported that miR-1 may control cell proliferation and cell cycle in human osteosarcoma through modulation of MET protein expression ([@b50-mmr-17-01-0771]). miR-1 may also inhibit gastric cancer cell proliferation by targeting MET ([@b51-mmr-17-01-0771]). Furthermore, miR-1 has been reported to regulate heat shock protein 60 expression, thus contributing to glucose-mediated apoptosis in cardiomyocytes ([@b52-mmr-17-01-0771]). Overexpression of miR-1 may also induce apoptosis in mesothelioma cell lines ([@b53-mmr-17-01-0771]). miR-1 has also been revealed to be involved in the protective effects of hydrogen sulfide against cardiomyocyte apoptosis via ischemia/reperfusion ([@b54-mmr-17-01-0771]). Introduction of miR-363 mimics has been reported to result in inhibition of cell proliferation in renal cell carcinoma ([@b55-mmr-17-01-0771]). Conversely, miR-363 may promote proliferation of human gastric cancer cells via targeting FBW7 ubiquitin ligase expression ([@b56-mmr-17-01-0771]). With regards to miR-449a, it has been reported to regulate proliferation in response to cisplatin by targeting cyclin D1 and Bcl-2 in SGC7901 cells ([@b57-mmr-17-01-0771]). In addition, overexpression of miR-449a significantly inhibits the proliferation of HEC-1B endometrial cancer cells ([@b58-mmr-17-01-0771]). miR-449a acts as a tumor suppressor by reducing the proliferation of human glioblastoma cell lines and glioblastoma stem cells ([@b59-mmr-17-01-0771]). miR-449a may also inhibit liver cancer cell proliferation by suppressing POU class 2 homeobox 1 and calpain 6 ([@b60-mmr-17-01-0771]). miRNAs have various target genes and serve roles in several diseases by regulating the associated target genes, thus, some miRNAs have exhibited opposing effects in different studies. OPC transplantation may alter miRNA expression following SCC in rats, and may be useful for treating SCC. To the best of our knowledge, the present study is the first to identify OPC transplantation-responsive spinal cord miRNAs in rats subjected to SCC, which may suggest potential functional roles for these miRNAs in transplantation of OPCs in rats with SCC.

In conclusion, the present study demonstrated that OPC transplantation could improve motor recovery and relieve mechanical allodynia of rats with SCC. After verifying the results of a miRNA assay, the most highly upregulated (miR-375-3p and miR-1-3p) and downregulated (miR-363-3p, miR-449a-5p and miR-3074) spinal cord miRNAs were detected in SCC rats transplanted with OPCs. These results suggested that OPC transplantation may promote functional recovery of rats with SCC, which may be associated with various miRNAs in the spinal cord, particularly miR-375-3p, miR-1-3p, miR-363-3p, miR-449a-5p and miR-3074.
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![Identification of GFP-OPCs. GFP-OPCs induced from induced pluripotent stem cells derived from mouse embryonic fibroblasts were cultured in differentiation medium for 24 days. Subsequently, cells were cultured in basal-OPC-medium containing PDGF. (A) PDGF staining was conducted, and \>90% of cells expressed PDGF. (B) DAPI nuclear staining was used to counterstain the cells (blue staining). (C) GFP detection indicated that cells displayed bipolar or tripolar morphology, which is typical of OPCs. (D) Merged image. Scale bar: 25 µm. GFP, green fluorescent protein; OPCs, oligodendrocyte precursor cells; PDGF, platelet-derived growth factor.](MMR-17-01-0771-g00){#f1-mmr-17-01-0771}

![Results of behavioral analyses. (A) With the exception of day 1 and 3, treatment with OPCs resulted in significantly higher BBB scores compared with in the Medium group. (B) Mechanical allodynia data from the paw withdrawal threshold analysis. On days 1 and 3 post-transplantation, the OPC, Medium and SCC groups exhibited a decreased paw withdrawal threshold, indicating mechanical allodynia, compared with in the Sham group. Rats in the OPC group exhibited significant attenuation of paw withdrawal threshold compared with in the Medium group. \*P\<0.05, \*\*P\<0.01 vs. the Medium group. BBB, Basso, Beattie and Bresnahan; OPC, oligodendrocyte precursor cell; SCC, contusive spinal cord injury.](MMR-17-01-0771-g01){#f2-mmr-17-01-0771}

![Significant differentially expressed miRNAs. (A) Top 10 upregulated miRNAs and 5 downregulated miRNAs. (B and C) Heat map of the 15 significant differentially expressed miRNAs. miR/miRNA, microRNA; OPC, oligodendrocyte precursor cell.](MMR-17-01-0771-g02){#f3-mmr-17-01-0771}

![GO analysis of the target genes of differentially expressed miRNAs. (A) Top 10 significantly enriched GO terms associated with the target genes of the 40 upregulated miRNAs. (B) Top 10 significantly enriched GO terms associated with the target genes of the 5 downregulated miRNAs. Numbers indicate the number of genes enriched in that GO term. GO, Gene Ontology; miRNA, microRNA.](MMR-17-01-0771-g03){#f4-mmr-17-01-0771}

![Kyoto Encyclopedia of Genes and Genomes pathway analysis of the target genes of differentially expressed miRNAs. (A) Top 10 significant pathways of the target genes of the 40 upregulated miRNAs. (B) Top 10 significant pathways of the target genes of the 5 downregulated miRNAs. Numbers indicate the number of genes enriched in that pathway. miRNA, microRNA.](MMR-17-01-0771-g04){#f5-mmr-17-01-0771}

![Verification of miRNA expression profiles in the spinal cord of rats in the OPC group compared with in the Medium group. The relative expression levels of the most significantly altered miRNAs were examined using quantitative polymerase chain reaction in the spinal cord of rats from the Medium and OPC groups. (A and B) Relative expression levels of rno-miR-375-3p and rno-miR-1-3p, which were revealed to be upregulated in a miRNA assay. \*\*P\<0.01. (C) Relative expression levels of rno-miR-363-3p, rno-miR-449a-5p and rno-miR-3074, which were revealed to be downregulated in a miRNA assay. miR/miRNA, microRNA; OPC, oligodendrocyte precursor cell.](MMR-17-01-0771-g05){#f6-mmr-17-01-0771}

###### 

Animals and grouping.

  Group    BBB score (no. of rats)   miRNA chip (no. of rats)   qPCR (no. of rats)
  -------- ------------------------- -------------------------- --------------------
  Sham     5                         0                          0
  SCC      5                         0                          0
  Medium   5                         3                          3
  OPC      5                         3                          3

BBB score was measured on days 1, 3, 7, 14, 21 and 28 post transplantation; miRNA chip analysis and qPCR were conducted on day 7. BBB, Basso, Beattie and Bresnahan; miRNA, microRNA; OPC, oligodendrocyte precursor cells; SCC, contusive spinal cord injury; qPCR, quantitative polymerase chain reaction.

###### 

Primer sequence catalogue numbers for miRNAs.

  miRNA             Number
  ----------------- ------------
  rno-miR-375-5p    RmiRQP3367
  rno-miR-1-3p      RmiRQP1188
  rno-miR-363-3p    RmiRQP3254
  rno-miR-449a-5p   RmiRQP0504
  rno-miR-3074      RmiRQP1482

miRNA, micro RNA.

###### 

Differentially expressed miRNAs in the spinal cord of rats from the oligodendrocyte precursor cell transplantation group compared with the Medium group.

  miRNA              log2 (fold change)   Expression   Species               Sequence length (bp)   Sequence (5′-3′)
  ------------------ -------------------- ------------ --------------------- ---------------------- --------------------------
  rno-miR-1-3p       3.932485             Up           *Rattus norvegicus*   22                     UGGAAUGUAAAGAAGUGUGUAU
  rno-miR-496-3p     2.874668             Up           *Rattus norvegicus*   21                     AGUAUUACAUGGCCAAUCUCC
  rno-miR-758-3p     2.632376             Up           *Rattus norvegicus*   22                     UUUGUGACCUGGUCCACUAACC
  rno-miR-206-3p     2.552146             Up           *Rattus norvegicus*   22                     UGGAAUGUAAGGAAGUGUGUGG
  rno-miR-375-3p     2.413651             Up           *Rattus norvegicus*   22                     UUUGUUCGUUCGGCUCGCGUGA
  rno-miR-133a-3p    2.264416             Up           *Rattus norvegicus*   22                     UUUGGUCCCCUUCAACCAGCUG
  rno-miR-379-3p     2.227997             Up           *Rattus norvegicus*   22                     CUAUGUAACAUGGUCCACUAAC
  rno-miR-335        2.224635             Up           *Rattus norvegicus*   23                     UCAAGAGCAAUAACGAAAAAUGU
  rno-miR-133b-3p    2.198147             Up           *Rattus norvegicus*   22                     UUUGGUCCCCUUCAACCAGCUA
  rno-miR-21-3p      2.15513              Up           *Rattus norvegicus*   22                     CAACAGCAGUCGAUGGGCUGUC
  rno-miR-134-3p     1.966194             Up           *Rattus norvegicus*   22                     CUGUGGGCCACCUAGUCACCAA
  rno-let-7a-2-3p    1.875046             Up           *Rattus norvegicus*   22                     CUGUACAGCCUCCUAGCUUUCC
  rno-miR-764-5p     1.757712             Up           *Rattus norvegicus*   22                     GGUGCUCACAUGUCCUCCUCCA
  rno-miR-369-5p     1.688398             Up           *Rattus norvegicus*   22                     AGAUCGACCGUGUUAUAUUCGC
  rno-miR-485-3p     1.6806526            Up           *Rattus norvegicus*   22                     CAUACACGGCUCUCCUCUCUUC
  rno-miR-376a-3p    1.67571              Up           *Rattus norvegicus*   21                     AUCGUAGAGGAAAAUCCACGU
  rno-miR-133a-5p    1.5515371            Up           *Rattus norvegicus*   22                     AGCUGGUAAAAUGGAACCAAAU
  rno-miR-124-5p     1.505714             Up           *Rattus norvegicus*   22                     CGUGUUCACAGCGGACCUUGAU
  rno-miR-218a-5p    1.499168             Up           *Rattus norvegicus*   21                     UUGUGCUUGAUCUAACCAUGU
  rno-miR-323-3p     1.491767             Up           *Rattus norvegicus*   21                     CACAUUACACGGUCGACCUCU
  rno-miR-361-3p     1.343701             Up           *Rattus norvegicus*   24                     CCCCCAGGUGUGAUUCUGAUUCGU
  rno-miR-500-5p     1.336195             Up           *Rattus norvegicus*   24                     AAUCCUUGCUAUCUGGGUGCUUAG
  rno-miR-20a-3p     1.3328006            Up           *Rattus norvegicus*   21                     ACUGCAUUACGAGCACUUACA
  rno-miR-493-3p     1.332116             Up           *Rattus norvegicus*   21                     UGAAGGUCUACUGUGUGCCAG
  rno-miR-551b-3p    1.316522             Up           *Rattus norvegicus*   23                     GGCGACCCAUACUUGGUUUCAGU
  rno-miR-122-5p     1.3071               Up           *Rattus norvegicus*   22                     UGGAGUGUGACAAUGGUGUUUG
  rno-miR-764-3p     1.268782             Up           *Rattus norvegicus*   23                     GAGGAGGCCAUAGUGGCAACUGU
  rno-miR-433-5p     1.248092             Up           *Rattus norvegicus*   22                     UACGGUGAGCCUGUCAUUAUUC
  rno-miR-411-5p     1.203803             Up           *Rattus norvegicus*   21                     UAGUAGACCGUAUAGCGUACG
  rno-miR-200b-5p    1.201743             Up           *Rattus norvegicus*   22                     CAUCUUACUGGGCAGCAUUGGA
  rno-miR-511-3p     1.200015             Up           *Rattus norvegicus*   21                     AAUGUGUAGCAAAAGACAGGA
  rno-miR-380-3p     1.17496              Up           *Rattus norvegicus*   21                     UAUGUAGUAUGGUCCACAUCU
  rno-miR-137-5p     1.142088             Up           *Rattus norvegicus*   22                     ACGGGUAUUCUUGGGUGGAUAA
  rno-miR-292-3p     1.134055             Up           *Rattus norvegicus*   23                     AAGUGCCGCCAGGUUUUGAGUGU
  rno-miR-381-5p     1.117327             Up           *Rattus norvegicus*   22                     AGCGAGGUUGCCCUUUGUAUAU
  rno-miR-873-3p     1.064982             Up           *Rattus norvegicus*   21                     GAGACUGACAAGUUCCCGGGA
  rno-miR-10b-3p     1.063514             Up           *Rattus norvegicus*   21                     ACAGAUUCGAUUCUAGGGGAA
  rno-miR-434-5p     1.02408              Up           *Rattus norvegicus*   23                     AGCUCGACUCAUGGUUUGAACCA
  rno-miR-205        1.015991             Up           *Rattus norvegicus*   23                     UCCUUCAUUCCACCGGAGUCUGU
  rno-miR-154-5p     1.003104             Up           *Rattus norvegicus*   22                     UAGGUUAUCCGUGUUGCCUUCG
  rno-miR-92a-1-5p   −1.138072            Down         *Rattus norvegicus*   23                     AGGUUGGGAUUUGUCGCAAUGCU
  rno-miR-449a-5p    −1.414279            Down         *Rattus norvegicus*   22                     UGGCAGUGUAUUGUUAGCUGGU
  rno-miR-363-3p     −1.172769            Down         *Rattus norvegicus*   21                     AAUUGCACGGUAUCCAUCUGU
  rno-miR-449c-3p    −1.0767871           Down         *Rattus norvegicus*   17                     UAGAACUUCGUCCCAAC
  rno-miR-3074       −1.463293            Down         *Rattus norvegicus*   22                     GAUAUCAGCUCAGUAGGCACCG

miR/miRNA, microRNA.

###### 

Statistical annotation of miRNA function.

  GO ID/pathway function term                                                         Gene count   P-value
  ----------------------------------------------------------------------------------- ------------ -----------------
  miR-375 and miR-1 common targets                                                                 
    GO:0045893-positive regulation of transcription, DNA-dependent                    2            1.96792×10^−24^
    GO:0045944-positive regulation of transcription from RNA polymerase II promoter   2            9.15325×10^−21^
    GO:0006351-transcription, DNA-dependent                                           1            2.48966×10^−15^
    GO:0000122-negative regulation of transcription from RNA polymerase II promoter   1            5.12873×10^−13^
    GO:0006355-regulation of transcription, DNA-dependent                             1            5.9179×10^−13^
    GO:0006417-regulation of translation                                              1            0.000151831
    GO:0006486-protein glycosylation                                                  1            1.21081×10^−10^
    GO:0006915-apoptotic process                                                      3            3.19378×10^−10^
    GO:0043066-negative regulation of apoptotic process                               3            7.94504×10^−10^
    GO:0043065-positive regulation of apoptotic process                               1            2.34005×10^−6^
    GO:0051402-neuron apoptotic process                                               1            1.43174×10^−5^
    GO:0043524-negative regulation of neuron apoptotic process                        2            7.17984×10^−6^
    GO:0008283-cell proliferation                                                     3            0.001320952
    GO:0008285-negative regulation of cell proliferation                              1            3.71268×10^−10^
    GO:0008284-positive regulation of cell proliferation                              4            4.37506×10^−10^
    GO:0042552-myelination                                                            2            0.0003695
    GO:0035556-intracellular signal transduction                                      3            1.05697×10^−10^
    GO:0000165-MAPK cascade                                                           1            0.000318552
    Path_id:1100-Metabolic pathways                                                   4            7.89723×10^−14^
    Path_id:4144-Endocytosis                                                          1            2.5492×10^−13^
    Path_id:4010-MAPK signaling pathway                                               1            4.94224×10^−11^
    Path_id:4020-Calcium signaling pathway                                            2            1.24247×10^−8^
    Path_id:4070-Phosphatidylinositol signaling system                                1            1.86855×10^−7^
    Path_id:4310-Wnt signaling pathway                                                1            2.71935×10^−7^
    Path_id:4151-PI3K-Akt signaling pathway                                           5            1.92934×10^−5^
    Path_id:3015-mRNA surveillance pathway                                            1            0.000876288
    Path_id:4064-NF-κB signaling pathway                                              2            0.008087159
    Path_id:4514-Cell adhesion molecules (CAMs)                                       1            0.048139487
  miR-363, miR-449a and miR-3074 common targets                                                    
    GO:0000122-negative regulation of transcription from RNA polymerase II promoter   2            9.32468×10^−5^
    GO:0045944-positive regulation of transcription from RNA polymerase II promoter   3            0.000267853
    GO:0006355-regulation of transcription, DNA-dependent                             1            0.006384786
    GO:0006468-protein phosphorylation                                                1            2.21252×10^−6^
    GO:0015031-protein transport                                                      1            0.032924475
    GO:0030182-neuron differentiation                                                 2            6.76381×10^−5^
    GO:0008285-negative regulation of cell proliferation                              1            0.003549981
    GO:0007264-small GTPase mediated signal transduction                              1            0.014162188
    GO:0007165-signal transduction                                                    2            0.044607167
    Path_id:4630-Jak-STAT signaling pathway                                           2            0.009890945

GO, Gene Ontology; Jak, Janus kinase; MAPK, mitogen-activated protein kinase; miR/miRNA, microRNA; NF-κB, nuclear factor-κB; PI3K, phosphoinositide 3-kinase; STAT, signal transducer and activator of transcription.
